Medical/Pharmaceuticals
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (" Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights inMexico for the commercialization of clobetasol propionate ophthalmic...
2025-05-07 06:30
3941
FutureLink Boston 2025 Reinforces TraceLink's Leadership in Supply Chain Orchestration and Innovation
BOSTON, May 7, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, successfully hosted FutureLink Boston 2025, bringing together more than 150 attendees ranging across senior executives, industry experts, and supply chain tech...
2025-05-07 00:39
2343
Plasmidsaurus Opens 10th Global Lab in Singapore, Scaling to Meet the Demand for Cutting-Edge Sequencing Around the World
SINGAPORE and SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Plasmidsaurus, the company that sequences while you sleep, today announced the opening of its tenth global sequencing lab, located inSingapore's vibrant biomedical hub. The new site dramatically shortens turnaround times for ...
2025-05-06 23:56
2750
Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. MT PLEASANT, S...
2025-05-06 22:12
3018
Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Almac Discovery, aNorthern Ireland-based research driven drug discovery company, for exclusive rights to the commercializ...
2025-05-06 21:00
3802
SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats
* Company aims to develop a bird flu vaccine with rapid mass production and variant responsiveness. * SK bioscience and KDCA join forces to build a national pandemic preparedness and response system for potential next-pandemic avian influenza. * "We will promote global public health and grow...
2025-05-06 20:00
2661
"Gedeon Richter House of Hope" opens its doors to support 300 women annually in Africa-Bamako
BUDAPEST, Hungary, May 6, 2025 /PRNewswire/ -- A center providing healthcare and educational support as well as shelter for vulnerable women has beenbuilt in Bamako, the capital of Mali, with financial assistance from Gedeon Richter. As one of the world's leading manufacturers of women's healthca...
2025-05-06 19:01
2282
Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be presented at the 32nd European Congress On Obesity (E...
2025-05-06 16:55
2692
Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy
– Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund – Proceeds will support the Phase 1/2 clinical trial of lead candidate, NVC-001, in patients with LMNA-related d...
2025-05-06 13:00
2824
Asia Pacific Initiative on Reproduction (ASPIRE) 2025 Congress: Fatherhood role models a new focus in filling the gap between actual and desired family sizes
SINGAPORE, May 6, 2025 /PRNewswire/ -- Presenting fatherhood as cool, admirable and masculine is likely to headline a new fertility rebound initiative across theAsia Pacific region as birth rates continue to fall at alarming levels. Renowned reproductive endocrinologist Emeritus Professor Domin...
2025-05-06 12:45
2429
Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform
GUANGZHOU, China, May 5, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online platform,...
2025-05-06 10:01
2171
Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025
SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2025-05-06 08:00
2998
Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial
BEIJING, May 5, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagoni...
2025-05-06 07:00
2127
INTREPID Alliance Releases New Report Highlighting Urgent Gaps in Antiviral Preparedness
Global antiviral R&D is slowing when the world can least afford it, new analysis shows CAMBRIDGE, Mass., May 6, 2025 /PRNewswire/ -- The INTREPID Alliance today released the fourth edition of itsAntiviral Clinical and Preclinical Development Landscape, a comprehensive analysis of the global pi...
2025-05-06 02:16
2005
Genezen and Optieum Biotechnologies Partner to Support cGMP Manufacturing of Groundbreaking CAR-T Therapy for Glioblastoma
Collaboration supports manufacture of the OPTF01 product to Drive Next-Generation Chimeric Antigen Receptor T Cell (CAR-T) Development INDIANAPOLIS and EHIME, Japan, May 5, 2025 /PRNewswire/ -- Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Optieu...
2025-05-05 21:00
2191
Revolutionary test for male infertility can be a game changer for couples striving to conceive
SINGAPORE, May 5, 2025 /PRNewswire/ -- A simple, but revolutionary test has been developed to help unravel the mystery of infertility among men who display normal semen parameters. Infertility affects an estimated one in every six couples worldwide with male factor prevalent in about half of t...
2025-05-05 09:00
2632
IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance
SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial inthe United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS07...
2025-05-04 14:48
3242
A future of reproductive medicine where humanity and trust sit in harmony with spectacular advances in artificial intelligence
SINGAPORE, May 3, 2025 /PRNewswire/ -- Artificial intelligence, or AI, is transforming our lives in dynamic and challenging ways, including the ability to create life. In assisted reproduction, AI and automation tools have taken fertility specialists to new frontiers in precision, efficiency a...
2025-05-03 09:47
4396
Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation
* Seegene previews a concept video of CURECATM at ESCMID Global 2025, ahead of its anticipated debut in July * With a fully modular design, CURECATM introduces a bold vision for automating pre-treatment across diverse PCR specimen types * Developed for future integration into unattended work...
2025-05-02 21:00
5272
Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
PHILADELPHIA, May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the14th International Bone Morphogenetic Protein (BMP) Conference, taking ...
2025-05-02 19:30
2928
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 321 media titles]
2026-02-19 14:30
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 301 media titles]
2026-02-23 08:00
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 280 media titles]
2026-02-17 19:12
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 279 media titles]
2026-02-23 10:09
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 259 media titles]
2026-02-17 14:16